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ABSTRACT 
Background/purpose: Narrowband UVB phototherapy is a common treatment modality in psoriasis and 
atopic dermatitis, but evidence of its actual effect in clinical setting is sparse. Our aim was to assess the 
effectiveness and costs of narrowband UVB phototherapy in psoriasis and atopic dermatitis in clinical 
setting. 
Methods: We observed 207 psoriasis patients and 144 atopic dermatitis patients in eight centers. SAPASI, 
PO-SCORAD and VAS measures were used at baseline, at the end and three months after the narrowband 
UVB phototherapy course. Quality of life was measured using DLQI and costs were assessed using a 
questionnaire. 
Results: Both in psoriasis and in atopic dermatitis the DLQI and SAPASI/PO-SCORAD improved 
significantly and the results remained improved for at least three months in both groups. Alleviation of 
pruritus correlated to better quality of life in both patient groups. We reported slight redness and burning 
side-effects which were due to lack of MED testing. Self-administered tools proved to be useful in 
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evaluating pruritus and severity of the disease in psoriasis and atopic dermatitis. Mean patient costs were 
310 € and 21 hours of time, and mean costs for the healthcare provider were 810 €. 
Conclusion: In psoriasis, narrowband UVB is a very efficient treatment in clinical setting, whereas in 
atopic dermatitis more studies are needed to determine the best dosage. 
 
Key words: PO-SCORAD, SAPASI, DLQI, PASI, SCORAD 
 
INTRODUCTION 
Psoriasis and atopic dermatitis (AD) are skin diseases that deteriorate the patient’s health-related quality 
of life (HRQoL) (1-3). Both skin diseases improve with narrowband ultraviolet B (NB-UVB) phototherapy 
(4). In a controlled setting, NB-UVB was shown to improve also HRQoL of psoriasis patients (5). NB-UVB 
therapy is regarded suitable for psoriasis patients with 10% or more body surface area affected by 
psoriasis and/or if the condition has not responded to topical treatment (6-8). Outcomes of NB-UVB 
phototherapy in AD are less studied. NB-UVB was shown to improve the HRQoL of children with AD (2), 
and in twelve AD patients at least 50% reduction was found in the Scoring of Atopic Dermatitis (SCORAD) 
questionnaire (9). 
   Alleviation of a skin disease can be assessed using various scoring systems, which are mostly aimed for 
professionals, such as the Psoriasis Area and Severity Index (PASI) and SCORAD (10,11). Nowadays 
patients are expected to take more responsibility of their care, and various patient-oriented measures, 
such as the Self-Administrated PASI (SAPASI) (12,13) and the Patient-Oriented SCORAD (PO-SCORAD) 
have been developed (14). The self-administrated measures could also empower patients. Dermatology 
Life Quality Index (DLQI) is an established measure of HRQoL (15). Both patients and professionals may 
take use of it. The DLQI score ranges from 0 to 30 and scores over 10 indicate problems in HRQoL. 
   Outcomes of randomized and strictly guided studies might differ from those achieved in clinical 
practice. Therefore, little is known about how NB-UVB works in clinical context and observational clinical 
studies are needed. The Finnish Photo-Dermatology Section updated the national guidelines of NB-UVB 
phototherapy in 2012. These include a dosing schedule for NB-UVB treatment of AD patients, and two 
tentative dosing schedules for psoriasis patients with either skin photo-type II or III– IV (16). 
   The costs of phototherapy can be significant for the healthcare sector and patients. The annual cost of 
UVB-phototherapy for the healthcare provider has been estimated to be between USD 3000–4800, 
including outpatient visits and phototherapy (17,18). With lower phototherapy unit costs, and without 
office visit costs, phototherapy has been estimated to cost EUR 1105 annually (19). Indirect costs, such as 
time and travel costs, can be significant for the patient. In a Dutch study, the indirect costs were estimated 
to be 75% of phototherapy costs (20). In a U.S. study, travel costs of a three-month phototherapy course 
were estimated to be USD 461–2306 depending on the distance, and total costs including phototherapy, 
copayments and lost wages USD 1871–4864 (21). Phototherapy costs after reimbursement vary between 
countries due to different social systems and insurances. 
   Our observational multi-center study was aimed to verify how the ordinary NB-UVB phototherapy in 
public out-patient dermatologic clinics impacts psoriasis and AD with specific emphasis on HRQoL. Since 
there is little data about the costs of NB-UVB in Finland, we calculated the costs for the healthcare 
provider and patients. 
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METHODS 
This study was organized as a multi-center study and the protocol was approved by the Ethics Committee 
of Tampere University Hospital (N:o R12118). All five university hospitals of Finland and three central 
hospitals from Southern Finland participated the study (Supplement 1). The data was collected in 2012–
2014. 
Patients and the narrowband UVB phototherapy course 
   Each clinic was asked to recruit at least 25 psoriasis and 25 AD patients taking advantage of arriving 
referrals. Patients in the need of NB-UVB phototherapy were considered eligible. Volunteering patients 
gave their informed consent. Subjects being pregnant or under 18 years old were excluded, and as a rule, 
patients with photosensitivity or photosensitizing drugs did not receive phototherapy. No further 
instructions were given on how to implement the phototherapy; each clinic was expected to conduct it 
using their best knowledge and the national guidelines. In our national NB-UVB guidelines, the proposed 
initial dose for AD is 0.20 J/cm2 with 10% increments. For psoriasis patients with Fitzpatrick’s skin 
photo-type II, the initial dose is 0.20 J/cm2 with 20% increments, and for psoriasis patients with photo-
types III-IV, 0.30 J/cm2 with 20% increments. During phototherapy, patients could use their routine 
systemic or topical medications, which were recorded in the files by the staff together with UVB doses 
and possible side effects. 
   The phototherapies were administered using Waldmann UV 7002 cabin equipped with 42 TL-01 t  es 
  ch  ze    o hm   r  h , Germany) in four hospitals, and Waldmann UV 7001 cabin equipped with 20 TL-
01 tubes (Waldmann, Villingen-Schwenningen, Germany) in four hospitals. In Päijät-Häme Central 
Hospital the cumulative NB-UVB doses were also measured using personal dosimeters (VioSpor blue line 
Type III, BioSense, Bornheim, Germany). The meters detect a dose ranging from 1.5 to 90 Standard 
Erythema Dose (SED) and are suitable for measurements of artificial lamps with different spectral 
compositions, such as TL-01 (22). One SED is equivalent to an erythemal effective radiant exposure of 10 
mJ/cm2 CIE (23). The dosimeters were attached to the patients’ wrists (24). A previously measured lamp 
spectrum was used for the NB-UVB dose calculations (25). 
Assessment of disease activity and HRQoL  
Patients do not routinely score their disease severity or HRQoL even if it might be useful, but we asked 
them to do so. The psoriasis patients filled in the SAPASI (12,13) and AD patients the PO-SCORAD (14) 
measures. Pruritus and disease severity were assessed globally using the Visual Analogue Scales (VAS) 
(26). HRQoL was assessed using DLQI, and the change in DLQI was the principal outcome measure 
(15,27). All measures were filled in three times: at baseline, at the end of the NB-UVB course, and three 
months after the course. 
Assessment of phototherapy costs 
Direct costs for the patient and the healthcare provider were assessed, but not costs of productivity losses 
for the employer. A questionnaire was used to assess time and travel costs. Travel costs were calculated 
using distances reported by the patients, between their home and the phototherapy unit, together with 
the number of visits related to phototherapy. For one-way distances less than 12.5 km, a regional bus fee 
of 2.5 € was app ied. For distances  eyond 12.5 km  a Social Insurance Institution of Finland 
reimbursement cost of 0.20 €/km was used. 
   Patients reported the average time needed for travelling and administering phototherapy. Time was not 
transformed to monetary losses, which vary depending on employment status. For example, employees 
and entrepreneurs suffer different time costs since employees can generally use their working time for 
health care visits, whereas entrepreneurs suffer monetary costs for their lost time personally. 
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   The copayment charge for an outpatient visit to a tertiary level hospital in 2012 was 27.50 €. For 
phototherapy, the charge was 7.50 € per visit. Total visit costs were calculated assuming only one 
dermato ogist’s appointment, prior the phototherapy course, which is the typical situation. Medication 
costs were not included, because these are compensated by a separate national insurance, which was not 
the focus of our study.  
   In the public sector, funding of phototherapy is based on taxing of municipalities, and the small 
copayment paid by the patient. The Finnish National Institute for Health and Welfare has published the 
unit costs for healthcare for 2011. Accordingly, the average dermato ogist’s appointment fee at a tertiary 
hospita  was 199 € and a 30-minute nurse appointment was 34 €.  ultimately charged from the 
municipalities.  
Sample size calculation 
The minimum size of the patient cohorts was calculated assuming that a clinically significant difference in 
DLQI is 5 points, with an α-va  e of 0.05 and a β-value of 0.90 (28). An assumed SD of 5.5 was used (27). 
Accordingly, it was considered necessary that at least 25 psoriasis patients and 25 AD patients per 
hospital should complete the study, in order to compare results between the hospitals. 
Statistics 
Statistical comparisons between psoriasis patients and AD patients were made using the t-test, chi-square 
test, or Fisher-Freeman-Halton test. Mean changes in DLQI and disease activity during the NB-UVB 
phototherapy were assessed using the paired t-test with Hoch erg’s approach for multiple comparison. 
The data is presented using mean ± SD, unless stated otherwise. Stata 15.0 (StataCorp LP; College Station, 
Texas, USA) statistical package was used for the analysis. 
 
RESULTS 
Patients 
A total of 207 psoriasis patients and 144 AD patients completed the study. The majority of psoriasis 
patients were males (n=119, 57%), but the majority of AD patients were females (n=95, 66%) (p<0.001). 
The mean age of psoriasis patients was 51 years (range 18–77) and AD patients 34 years (range 18–79) 
(p<0.001). The Fitzpatrick’s skin photo-types I to IV were presented in frequency of 7/64/115/21 for 
psoriasis and 6/58/71/9 for AD patients (p=0.22). There were seven patients with psoriatic arthritis, and 
19 patients were taking acitretin, one methotrexate, one etanercept and one prednisolone. Seven AD 
patients were taking prednisolone. The minimum desired number of participants of 25 was gained in only 
some of the hospitals, which made it impossible to compare the results (Supplement 1). 
Disease activity after NB-UVB phototherapy 
SAPASI depicting psoriasis severity decreased from 11.7 ± 7.4 by 8.6 units during the NB-UVB course 
(p<0.001). PO-SCORAD in AD patients decreased from the initial value of 40.4 ± 14.3 by 18.9 units 
(p<0.001). At the end of the course 29 (14%) of psoriasis patients were completely cleared, whereas only 
two (1.4%) of AD patients did so. A 75% clearance of SAPASI was observed in 109 (53%) of psoriasis 
patients. Respectively 25 (17%) of AD patients achieved 75% improvement using PO-SCORAD (Table 1). 
VAS depicting global disease severity and pruritus decreased statistically significantly in both patient 
groups (p<0.001). 
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Quality of life after NB-UVB phototherapy 
The main outcome measure, DLQI, improved in both patient groups highly significantly during NB-UVB 
(Fig. 1). In psoriasis patients DLQI improved from its initial value of 10.1 ± 6.5 by 6.3 (p<0.001), and in AD 
patients from 12.9 ± 6.0 by 8.1 (p<0.001) (Table 1). 
   The initial SAPASI and PO-SCORAD showed moderate correlations to initial DLQI, r=0.47 (95% CI 0.35 
to 0.58, p<0.001), and r=0.43 (95% CI 0.28 to 0.56, p<0.001), respectively. Initial global disease severity 
VAS correlated with DLQI at the onset of the study in both patient groups (in psoriasis r=0.54, 95% CI 
0.44 to 0.63, p<0.001 and in AD r=0.32, 95% CI 0.16 to 0.46, p<0.001). The most important determinant 
of HRQoL was pruritus. In both patient groups the initial pruritus VAS correlated highly significantly with 
the initial DLQI values (in psoriasis r=0.58, 95% CI 0.49 to 0.66, p<0.001; and in AD r=0.45, 95% CI 0.29 
to 0.59, p<0.001) (Table 1). 
Disease activity and quality of life 3 months after NB-UVB phototherapy 
Three months after the NB-UVB course, SAPASI was still decreased from the baseline value by 4.9 units 
(p<0.001) and PO-SCORAD by 16.5 units (p<0.001). VAS depicting global disease severity and pruritus 
were still significantly decreased in both patient groups (p<0.001). DLQI was still decreased in psoriasis 
patients by 3.8 units (p<0.001) and in AD patients by 8.0 units (p<0.001, Fig. 1). 
NB-UVB phototherapy course 
During the NB-UVB course, psoriasis patients received a cumulative UVB dose of 16.4 ± 8.3 J/cm2 (96.5 ± 
48.4 SED) and AD patients 12.2 ± 5.5 J/cm2 (71.8 ± 32.4 SED). The number of NB-UVB exposures was 18 ± 
4 in psoriasis patients and 17 ± 4 in AD patients. The NB-UVB exposures were typically given three times 
a week. The duration of phototherapy was 7.7 ± 3.4 weeks in psoriasis and 7.3 ± 2.5 in AD patients (Table 
2). We analyzed the initial UVB doses in Päijät-Häme Central Hospital. The mean initial dose was 0.21 ± 
0.04 J/cm2 in psoriasis patients (n= 28), and 0.19 ± 0.04 J/cm2 in AD patients (n=27), being in agreement 
with the national guidelines. According to the patient records, some erythema was recorded in 66% of 
psoriasis patients, and severe erythema or skin burn in 8%.  Among AD patients 61% experienced some 
erythema during the NB-UVB course, whereas definite burns were seen in 13.9% (Table 2). In addition, 
eight psoriasis patients reported tingling and burning, seven pruritus, three dryness, two headache, one 
blistering, one tiredness and one fever. In AD patients, nine reported dryness, eight pruritus, four tingling 
and burning, two herpes simplex and one tiredness. 
Personal UV dosimeters 
The mean cumulative UVB dose measured using personal dosimeters in Päijät-Häme Central Hospital was 
47.3 ± 20.9 SED in psoriasis patients (n=18) and 47.1 ± 21.6 SED in AD patients (n=13). According to the 
internal dosimeter of the Waldmann cabin, the corresponding physical non-weighted doses were 13.9 ± 
6.1 J/cm2 in psoriasis patients (n=18) and 12.7 ± 4.3 J/cm2 in AD patients (n=13). Using a previously 
measured lamp spectrum, we calculated that these doses correspond to 81.8 SED and 74.7 SED, 
respectively. The calculated dose is thus 42% higher in psoriasis patients, and 37% higher in AD patients, 
than the dose measured using dosimeters. 
Phototherapy costs for the patients 
The mean one-way distance to the phototherapy unit was 15.0 km (95% CI 12.6 to 17.3 km, range 0.0 to 
250 km). The mean cumulative travel distance per patient was 569 km (95% CI 463 to 675km, range 0.0 
to 14000 km), which yielded a mean travel cost of 149 €  95% CI 129 to 169 €  range 40 to 2800 €). The 
mean time required for one phototherapy visit including travel time was 66 min (95% CI 61 to 72 min, 
range 5 to 690 min), which yielded a mean total phototherapy course time of 21 h (95% CI 19 h to 23 h, 
range 2 h to 242 h). The patients’ share of visit costs were on average 162 €  95% CI 159 to 166 €). The 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
mean tota  patient costs inc  ding trave  and phototherapy costs were 310 €  95% CI 289 to 331 €  range 
120 to 3030 €). 
 
Phototherapy costs for the healthcare provider 
The societa  costs of phototherapy inc  ding the dermato ogist’s appointment  and phototherapy sessions 
administered  y n rse  were on average 810 €  95% CI 795 to 825 €). 
 
DISCUSSION 
To our knowledge, our study is the first large scale clinically oriented study to show how NB-UVB 
phototherapy functions in the normal out-patient treatment context in psoriasis and AD. Using several 
outcome measures, we showed that NB-UVB phototherapy is an efficient regime in clinical use and 
improves the HRQoL of psoriasis and AD patients highly significantly using DLQI. This was also the 
primary outcome measure in this study. Improvement was maintained for at least three months in both 
groups. 
   Consistent with our study, psoriasis seems to be cleared more efficiently than AD in strictly steered 
intervention studies. Dawe at al. have shown even 100% clearance in psoriasis using NB-UVB, whereas 
others have shown for AD only moderate responses (29-31). Noteworthy the SAPASI and PO-SCORAD are 
not comparable. PASI and SAPASI measure visible signs, but SCORAD and PO-SCORAD involve subjective 
symptoms e.g. pruritus (12-14). 
   The g o a  meas res  sed in o r st dy: the “global disease severity VA ”  the “pruritus VA ” and DLQI 
measure the outcome globally and show a highly significant improvement. The results showed that NB-
UVB phototherapy works also clinically expectedly. A clearance of 75% or more using SAPASI and PO-
SCORAD was found in 50% of psoriasis patients, but only in 16% of AD patients. SAPASI and PO-SCORAD 
showed highly significant change in disease severity statistically. To our surprise, pruritus was equally 
frequent in both patient groups, although pruritus has earlier been shown to affect the HRQoL more in AD 
patients than in psoriasis patients (32). 
   NB-UVB phototherapy is indicated when topical treatments are not sufficient. Therefore, the severity of 
the skin condition is an important denominator when assessing the outcome. In our study the average 
severities of the skin conditions were either moderately severe or severe defined as DLQI > 10, SAPASI > 
10 or PO-SCORAD > 40 (Table 1). The patients were thus high need patients and the outcome of NB-UVB 
can be judged as optimal in agreement with Patrizi et al. (33). 
   In this multi-center study, the mean cumulative NB-UVB dose was 16.4 J/cm2 in psoriasis patients and 
12.2 J/cm2 in AD patients. A subset of patients used personal UV dosimeters, which measured a mean UVB 
dose of 47 SED in psoriasis and similarly 47 SED in AD. We have earlier assessed the UVB doses of a 2-
week heliotherapy with similar dosimeters and saw a mean cumulative dose of 30 SED in psoriasis and 
43 SED in AD patients (34).  During a high UV season even higher UVB doses, such as 60 and 109 SED, 
have been demonstrated in heliotherapy (35). Thus, the cumulative UVB dose during NB-UVB 
phototherapy compares to that of a 2-week heliotherapy. 
   We were surprised of high frequency of erythema at some stages of therapy in 66% of psoriasis and 
61% of AD patients. Definite burns were seen in 8% and 9% respectively. Mild erythema reactions were 
seen in 73% of psoriasis patients receiving NB-UVB in a strictly controlled randomized study, where the 
dosing was based on preceding Minimal Erythema Dose (MED) testing (36). However, the increments in 
that study were 30-40% initially differing from our moderate increments of 10–25%, and the treatment 
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was given twice a week. Diffey (2004) has shown using modeling that clearance of psoriasis is achieved 
faster using higher dosing (36). According to other studies, NB-UVB phototherapy functions at its best 
close to MED (31). To our knowledge, no such data is available for phototherapy of AD, and further 
studying is warranted. 
   MED testing is rarely performed preceding phototherapy in our country, and photo-testing devices may 
also be lacking on the site. Defining the skin photo-type without MED testing is a challenge (16,38-40). 
Therefore, the photo-types may not have been classified properly in the clinics explaining erythema 
reactions. In addition, there were skin photo-type I participants, which is a deviation of our national 
recommendation and must be discussed in our clinics. International guidelines suggest MED testing and 
using 70% of the MED as an initial dose (41). Increasing the use of MED testing could decrease erythema 
reactions. There are also technical tools available to predict UV dosing objectively (42). Due to increasing 
number of new medicines, the use of phototherapy has decreased and perhaps less emphasis is put on 
maintaining expertise. 
   The self-administered assessment tools fulfilled their task in this study. We were especially satisfied 
with the global VAS measures and DLQI showing respective outcome as the more laborious SAPASI and 
PO-SCORAD. To empower patients, the measures should be easy to calculate and interpret. Further 
studies with modifications of VAS are warranted in this purpose.  
   A 2-week heliotherapy has been shown to improve clinical signs and HRQoL of psoriasis and AD, and the 
improved HRQoL persisted in both patient groups for up to three months. Three months after 
heliotherapy, SAPASI remained decreased by 36% and PO-SCORAD by 40% (34). Autio et al. (2002) 
demonstrated a 45% decrease in SCORAD index 3 months after a 2-week heliotherapy (43). These results 
are comparable with the 42% SAPASI decrease and 41% PO-SCORAD decrease seen in the present study. 
   The costs of NB-UVB phototherapy were lower than in previous studies (17-19,44), probably because 
we included only one dermatologist’s appointment to the ca c  ations. Also, we did not register potential 
laboratory, pathology or hospitalization costs. Thus, our cost analysis represents the cost of an ideal NB-
UVB phototherapy course and represents at its best the minimum cost. 
   The advantage of our study is that this was a real-life follow-up study, not just register data or a random 
questionnaire. A limitation of our study is that only few departments recruited the desired 25 patients per 
group. The low figures (Supplement 1) did not mean that there was a shortage of patients, but rather that 
there was not enough staff or time to complete the study in a busy clinic. In addition, the time cost was 
not transformed to monetary costs, and earlier studies have shown that the burden of phototherapy falls 
on the patient and employee, who both may pay marked time-related cost (45,46). 
   We were able to show that NB-UVB phototherapy works well in a normal clinical setting and both 
psoriasis and AD patients showed highly significant alleviation of their skin conditions and improvement 
of their HRQoL. The improved situation, as seen in disease scores, global measures and DLQI, was 
sustained in both patient groups for at least three months confirming that earlier research outcomes 
coincide with clinical outcomes. The direct costs of NB-UVB phototherapy are reasonable or even cheap 
as regards severity of the skin conditions, but the invisible indirect costs may alter this. 
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Baseline
Δ After phototherapy
Δ 3 months after 
phototherapy
Mean (95% CI) Mean (95% CI)
Psoriasis
   DLQI 10.1 (6.5) -6.3 (-7.0 to -5.5)*** -3.8 (-4.6 to -2.9)***
   SAPASI 11.7 (7.4) -8.6 (-9.6 to -7.6)*** -4.9 (-6.0 to -3.8)***
   VAS pruritus 4.4 (2.7) -2.9 (-3.3 to -2.5)*** -1.4 (-1.9 to -1.0)***
   VAS global 5.8 (2.2) -3.3 (-3.7 to -3.0)*** -2.1 (-2.4 to -1.7)***
Atopic dermatitis
   DLQI 12.9 (6.0) -8.1 (-9.0 to -7.1)*** -8.0 (-9.3 to -6.8)***
   PO SCORAD 40.4 (14.3) -18.9 (-21.4 to -16.4)*** -16.5 (-20.0 to -12.9)***
   VAS pruritus 5.2 (2.4) -3.1 (-3.6 to -2.7)*** -2.5 (-3.1 to -1.9)***
   VAS global 5.1 (2.1) -2.9 (-3.3 to -2.5)*** -2.6 (-3.1 to -2.0)***
Change from baseline
Mean (SD)
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Psoriasis (n  = 207) Atopic dermatitis  (n  = 144) p -value
Initial NB-UVB radiation dose (J/cm2) 0.21 ± 0.04* 0.19 ± 0.04** 0.137
Cumulative NB-UVB radiation dose (J/cm2) 16.4 ± 8.3  3.5 – 48.5) 12.2 ± 5.5  3.0 – 29.1) < 0.001
Number of exposures 18 ± 4  7 – 30) 17 ± 4  8 – 30) 0.028
Duration of phototherapy (weeks) 7.7 ± 3.4 7.3 ± 2.5 0.119
Exposures per week 2/3/4 48/157/1 42/100/0 0.26
Patients with erythema 136 88 0.44
Patients with skin burn 17 13 0.92 
* Based on 28 psoriasis patients in Päijät-
Häme Central Hospital
** Based on 27 AD patients in Päijät-Häme 
Central Hospital
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